Background {#Sec1}
==========

The prevalence of multiple chronic conditions is on the rise which presents a significant burden to healthcare systems in Australia and worldwide \[[@CR1], [@CR2]\]. Recent advances in medicine and technology have resulted in increased life expectancy which has contributed to growth of the ageing population, surviving with increased years of disabilities and accumulation of chronic conditions \[[@CR3], [@CR4]\]. The Australian National Health Survey (NHS) 2017--18 data shows that chronic disease prevalence increases with age, with 80% of Australians aged 65 years and above having one or more chronic conditions \[[@CR5]\]. There is well-documented evidence of multimorbidity associated with increased risk of mortality \[[@CR6]\]; reduced functional status and quality of life \[[@CR7]\]; and increased health service utilisation \[[@CR8], [@CR9]\]. Furthermore, patients presenting with multimorbidity are often recipients of fragmented care, as healthcare systems, including Australia, still remain largely configured to management of single diseases, thereby lacking coordination and continuity of care \[[@CR10]\]. Contrarily, there is sound evidence suggesting that collaborative approaches in primary care are associated with effective management of chronic illnesses \[[@CR11], [@CR12]\].

Management of multimorbidity requires effective care delivery with emphasis on patient-tailored self-management treatment strategies for better patient outcomes \[[@CR11]\]. Patient-centred medical home (PCMH) model enables continuity of care through a comprehensive and coordinated approach and aims to improve self-management behaviours configured to individual needs \[[@CR13], [@CR14]\]. This enhanced primary care model is led by a general practitioner (GP) as part of a multidisciplinary team (MDT) of primary care providers, working together with patients, to promote proactive care that is targeted to the level of risk and complexity of patients \[[@CR13], [@CR15]\]. There is an increasing evidence on the effectiveness of PCMH models of care, primarily in United States, in improving patient activation and self-management of chronic diseases, leading to better quality of health and health utilisation outcomes \[[@CR16]--[@CR18]\]. However, the feasibility and effectiveness of the PCMH model remain unclear in Australian primary care practices.

In the past decade, there has been a growing advocacy towards patient engagement and self-management of chronic disease/s \[[@CR15], [@CR19]\]. Patient activation is defined as a multidimensional construct of one's readiness and ability to manage their own health as well as proactively engaging in making informed decisions about healthcare \[[@CR20], [@CR21]\]. The level of activation and ability to self-manage conditions play an important role in a patient's overall health and wellbeing, especially for those presenting with multimorbidity \[[@CR20], [@CR22]\]. There is a growing body of evidence indicating that patients who are actively engaged with the health care team have improved health-related quality of life and clinical outcomes \[[@CR23]--[@CR25]\]. In addition, patients with high activation levels are often empowered through shared decision-making with their GPs and are reported to have better adherence to the treatment regimens and lower hospital admissions compared to patients with lower activation scores \[[@CR26], [@CR27]\].

Understanding an individual's level of activation enables physicians to provide patient-tailored care according to the severity and complexity of the disease \[[@CR28]\]. Although chronically ill patients generally report low activation and have increased health care utilisation \[[@CR26]\], their levels of activation can be modified through effective education and training \[[@CR29]\]. Despite the growing advocacy towards patient activation and self-management, there is relatively little information about the levels of patient activation among individuals presenting with chronic illnesses in Australia. Therefore, this study aims to evaluate changes in the mean patient activation scores and to investigate significant predictors of patient activation following a 12-month PCMH intervention among individuals presenting with one or more chronic diseases in Sydney, Australia.

Methods {#Sec2}
=======

WellNet program and study design {#Sec3}
--------------------------------

Sonic Clinical Services (SCS) designed a 12-month chronic disease management (CDM) program called 'WellNet' which aims to provide a GP-led, MDT based care for patients with one or more chronic conditions. This enhanced primary care program is built upon the principles of the PCMH model and is guided by other evidence based, best practice models of clinical care in order to deliver high quality patient-centric care that is configured to individual risk and complexity levels \[[@CR30]\].

Patients were recruited between December 2016 and October 2017 using a targeted convenience sampling technique. Targeted convenience sampling is a commonly used non-probability sampling method in clinical research where members of the target population that meet certain practical eligibility criteria are included for the purpose of the study \[[@CR31]\]. We used a before-and-after case-series study design to evaluate the outcome of WellNet program in improving patient activation levels among primary care patients enrolled in six general practices in Northern Sydney, Australia. A written informed consent was obtained from the participants who enrolled in the 12-month study. A detailed description of the program design and evaluation are reported elsewhere \[[@CR30]\].

Participants {#Sec4}
------------

The Participant, Intervention, Comparator, and Outcome statement (PICO) is briefly summarised in Box 1 ([supplementary material](#MOESM1){ref-type="media"}). Potentially eligible patients (*N* = 1790) were contacted either through letter invites (*N* = 1431) or GP referrals (*N* = 359) for the initial assessment. Eligibility criteria included patients aged 40 years and above; having one or more chronic condition/s; who had consulted a GP three times in the previous 2 years; and had a Hospital Admission Risk Profile (HARP) score of more than 10. The HARP risk assessment tool determines the likelihood of people with chronic or complex care needs presenting to the hospital for treatment in the following 12 months \[[@CR32]\]. In addition, patients with one or more consistently elevated clinical risk factors were also invited to participate through GP referrals. Further details of the patient algorithm, recruitment outcomes, and data collection are reported elsewhere \[[@CR30]\].

Of the 1790 invited patients, 698 attended the initial assessment for eligibility and 10 patients were deemed ineligible to participate in the program due to reasons of living in nursing homes and diagnosis of severe cognitive impairment or terminal illness. Out of the eligible 688 patients, 52 declined to participate in the program due to unknown reasons, resulting in 636 patients. Of the 636 consenting participants, 626 reported their baseline PAM score and were included in this study. The flowchart of patient recruitment outcomes is shown in Fig. [1](#Fig1){ref-type="fig"}. Although the WellNet study includes a well-matched comparison group based on age, gender, type and number of chronic conditions, self-reported health assessments such as PAM assessments were recorded only among the treatment group. Therefore, the analyses were limited to within-group rather than between-group comparison with standard primary care (comparison group). Fig. 1Flowchart of patient enrolment

WellNet intervention {#Sec5}
--------------------

The 12-month WellNet program is designed to integrate GPs with specially trained chronic disease management (CDM) Care Coordinators (CC) within each of the six participating GP practices \[[@CR30]\]. On entry to the program, the team of GPs and CCs coordinate with patients to undertake a range of validated general and disease-specific risk assessments to determine patient's baseline health status and wellbeing. The information gathered from these assessments is then used to formulate an individualised CDM plan in consultation with the patient. Included in the care plan are patient driven health goals; modifying and training core skills to self-manage symptoms and medications; improving diet and physical activity; and reducing smoking and alcohol consumption \[[@CR30]\]. The care plan includes, and is shared with, all relevant members of the care team. Ongoing support to increase knowledge, understanding and maintenance of positive behaviour change; monitoring of progress towards health goals; and assistance to access health and social care are provided through a combination of in-practice and telephone contacts. A sample goal chart with timelines used by the care team to provide individualised care for patients diagnosed with type 2 diabetes, hypertension and depression is shown in Fig. [2](#Fig2){ref-type="fig"}. Fig. 2Sample goal chart for patients with type 2 diabetes, hypertension, and depression with timeline. SMS -- short message service; K10 -- Kessler's psychological distress scale; DASS21 -- Depression Anxiety Stress Scale 21 version; DE -- diabetes educator; GP -- general practitioner; BGL -- blood glucose level; BP -- blood pressure; HbA1c -- glycated haemoglobin; GI -- glycaemic index; CV risk -- cardiovascular risk

Furthermore, ongoing patient support is also supplemented through a user-friendly online platform and a mobile application. "GoShare" is an online web-based tool that enables digital sharing of evidence-based patient-relevant education materials. Patients' access to the materials and understanding of them are regularly monitored and assessed through self-reported surveys. The CCs focus on low adherence to usage or understanding, so that issues can be resolved. Furthermore, patients are also supported with a mobile application, called 'MediTracker', which links directly to their clinical records held at the practice, providing access to information such as their current medications, pathology results, diagnoses and immunisation status \[[@CR30]\]. This is intended to encourage and empower patients to play an active role in their chronic disease care management.

Patient activation measure 13 item version {#Sec6}
------------------------------------------

Patient activation was measured with use of the validated PAM-13 item version developed by Hibbard et al. \[[@CR21]\]. PAM-13 is a self-reported questionnaire composed of 13 items relating to patients' beliefs about healthcare, knowledge about their health condition, and confidence in managing health related tasks. Each item has five response options from 0 to 4 such as: (0) 'not applicable'; (1) 'strongly disagree'; (2) 'disagree'; (3) 'agree'; and (4) 'strongly agree'. The raw responses range from 13 to 52 which are then transformed through Insignia's proprietary natural logarithm to a standardised metric ranging from 0 to 100 (0 = lower activation; 100 = highest activation). The scores are classified into four levels of activation: Level 1 (≤47.0) -- not believing activation is important; Level 2 (47.1--55.1) -- Lacking knowledge or confidence in self-management of health; Level 3 (55.2--67) -- Beginning to take action; and Level 4 (≥67.1) -- Taking action but require support in maintaining positive behaviour change. Each of these levels provide insights into a range of health-related characteristics, including behaviours and outcomes \[[@CR28]\]. In addition, determining baseline scores allow MDT to determine the best approach to engage and educate patients and thus improve self-management behaviour. Studies reporting on validation of PAM scores indicate that the minimal clinically important difference (MCID) is at least a 4-point difference in PAM score in addition to transitioning from lower to higher PAM levels \[[@CR20], [@CR21]\]. MCID refers to the smallest change in an outcome score that is considered "important" or "worthwhile" by the practitioner and/or resulting in a change in patient management \[[@CR33]\]. Changes in outcomes exceeding this minimal threshold are considered clinically relevant \[[@CR33]\].

PAM scores were recorded from the patients at the start and completion (12 months) of the WellNet program. Aligned to the outcome of patient activation, key demographic information of age, gender, type and number of chronic conditions, private health insurance status, and total program contacts were analysed in this study.

Self-management impact and readiness to change scale of HARP assessment {#Sec7}
-----------------------------------------------------------------------

Item six of the HARP assessment reports on the self-management and readiness to change behaviours which includes several categories: No capacity for self-management; pre-contemplation (not ready for change) and contemplation (considering but unlikely to change); preparation (intending to take action in the immediate future); action (actively changing health behaviours) and maintenance (maintained behaviour for ≥6 months); and relapse. This scale was only used as a supplement to the PAM assessment.

Study outcomes {#Sec8}
--------------

The primary outcome of interest for this study was changes in the mean PAM score between baseline and 12-months after controlling for potential baseline covariates such as age, gender, type and number chronic disease diagnosis, insurance status, median visits, and baseline PAM score. Secondary outcomes include: 1) changes in proportion of patients with respect to different levels of PAM and HARP's self-management impact scale at follow-up; 2) association between PAM levels and self-management impact and readiness to change scale of the HARP risk assessment tool; 3) significant predictors of PAM scores at follow-up.

Data analysis {#Sec9}
-------------

Descriptive statistics for continuous variables using mean and standard deviation (SD) and percentages for categorical measures are presented in Table [1](#Tab1){ref-type="table"}. One-way analysis of variance (ANOVA) was conducted to test for significant between-group differences in means between levels of patient activation corresponding to each variable at baseline. Pearson's correlation coefficient test was also used to determine the association within and between PAM scores and HARP's self-management impact scale at baseline and follow-up respectively. Additionally, t-tests and chi-square tests were performed to determine any significant difference between patients who completed the program and those who withdrew from the program. Table 1Patient characteristics by level of patient activation at baselineVariableTotalPAM Level 1PAM Level 2PAM Level 3PAM Level 4Activation score Mean (SD)All participants626 (100)121 (19.1)236 (37.7)138 (22.0)131 (20.9)57.5 (13.1)Age in years, Mean (SD)\*68.8 (12.9)70.4 (12.5)70.5 (12.9)66.0 (12.9)67.0 (12.4)--**Median age group***≤ 70 years*318 (50.8)60 (18.9)107 (33.6)80 (25.2)71 (22.3)58.2 (13.3)*\> 70 years*308 (49.2)61 (19.8)129 (41.9)58 (18.8)60 (19.5)56.8 (12.8)**Gender***Males*313 (50.0)62 (19.8)121 (38.7)69 (22.0)61 (19.5)57.1 (12.9)*Females*313 (50.0)59 (18.8)115 (36.7)69 (22.0)70 (22.4)58.0 (13.3)**Diagnosis of chronic condition (grouped)**^a^*Circulatory system diseases*214 (34.2)44 (20.6)91 (42.5)41 (19.2)38 (17.8)55.7 (11.4)*Respiratory diseases*181 (28.9)39 (21.5)64 (35.4)44 (24.3)34 (18.8)57.3 (13.5)*Diabetes*307 (49.0)62 (20.2)112 (36.5)71 (23.1)62 (20.2)57.1 (12.0)*Musculoskeletal disorders*267 (42.7)58 (21.7)98 (36.7)54 (20.2)57 (21.3)57.5 (13.5)*Mental illness*127 (20.3)34 (26.8)48 (37.8)29 (22.8)16 (12.6)54.2 (11.4)*Cancer*92 (14.7)15 (16.3)35 (38.0)21 (22.8)21 (22.8)57.3 (13.1)**Number of co-existing conditions, Mean (SD)**1.9 (0.9)2.1 (1.0)1.9 (0.9)1.9 (0.9)1.7 (0.9)--**Insurance status\*\****Private*398 (68.7)60 (15.1)152 (38.2)89 (22.4)97 (24.4)59.0 (13.8)*Uninsured*181 (31.3)50 (27.6)74 (40.9)34 (18.8)23 (12.7)54.1 (10.4)**Total program contacts***≤ 11 contacts*320 (51.1)64 (20.0)119 (37.2)74 (23.1)63 (19.7)57.4 (13.4)*\> 11 contacts*306 (48.9)57 (18.6)117 (38.2)64 (20.9)68 (22.2)57.7 (12.8)**Clinical measures***Systolic Blood Pressure (mmHg), Mean (SD)*138.8 (19.1)138.6 (23.1)138.3 (17.7)139.4 (19.5)139.3 (17.3)--*Diastolic Blood Pressure (mmHg), Mean (SD)*75.9 (18.2)74.3 (19.5)76.2 (16.8)76.2 (18.0)76.4 (19.6)--*Body Mass Index Kg/m2, Mean (SD)*29.9 (7.3)31.2 (10.1)29.3 (6.1)30.1 (6.6)29.6 (6.5)--*Glycated Haemoglobin (%), Mean (SD)\**6.8 (1.4)7.1 (1.3)6.8 (1.3)6.9 (1.8)6.4 (1.1)--*High Density Lipoprotein Cholesterol (mmol/L), Mean (SD)*1.3 (0.4)1.3 (0.4)1.3 (0.4)1.3 (0.4)1.4 (0.4)--*Low Density Lipoprotein Cholesterol (mmol/L), Mean (SD)\**2.7 (1.1)2.6 (1.2)2.6 (1.0)2.8 (1.1)2.9 (1.1)--*Total Cholesterol (mmol/L), Mean (SD)\**4.8 (1.4)4.8 (1.6)4.6 (1.2)5.0 (1.3)5.2 (1.4)--*Triglyceride (mmol/L), Mean (SD)*1.6 (1.1)1.6 (0.9)1.7 (1.2)1.7 (1.1)1.6 (1.3)--Data presented as N (%) unless specified otherwiseVariables reported as percentages were tested with chi-square analyses and variables reported as means and standard deviations were tested with ANOVA^a^Specific chronic diseases were grouped as per the International Statistical Classification of Diseases and Related Health Problems (ICD-10) classification\**p*-value\< 0.05\*\**p*-value\< 0.001

Primary analysis included only those who reported both baseline and follow-up scores. Adjusted mean difference between baseline and follow-up was measured using repeated measures ANCOVA to control for baseline potential covariates such as age, gender, type and number chronic disease diagnosis, insurance status, and median visits. A sensitivity analysis was also conducted to evaluate adjusted differences in PAM scores between baseline and follow-up among patients with two or more chronic conditions.

Backward stepwise multivariable regression models were conducted to determine the predictors of PAM scores at 12-month follow-up. Independent baseline covariates tested against follow-up PAM scores in the univariate analysis included: age, gender, type and number chronic disease diagnosis, insurance status, median visits, and baseline PAM score. Any variable with *p*-value of \< 0.2 was then included in the multivariable model. The backward stepwise regression approach was used to reduce and create a final model while simultaneously assessing the fitness of the model in order to avoid dropping of non-significant variables that may affect the model fitness. The final model constitutes variables, which when excluded, cause a prominent deviance change (*p* \< 0.05) compared to the corresponding *X*^2^ test statistic on the relevant degrees of freedom.

Internal consistency of pre and post PAM-13 items in this study were evaluated using Cronbach's alpha. R and SPSS (version 25) statistical software were used to conduct all the analyses. Significance level was set as 0.05 and all statistical tests were two-sided.

Results {#Sec10}
=======

Baseline patient characteristics and activation levels {#Sec11}
------------------------------------------------------

The sociodemographic characteristics and chronic disease prevalence of the study sample by baseline PAM levels are presented in Table [1](#Tab1){ref-type="table"}. The mean age of the sample was 69 ± 13 years with equal gender distribution. The study patients had a mean number of 2 ± 1 co-existing chronic condition with diabetes (49%), musculoskeletal disorder (43%), and circulatory system disorders (34%) as the most prevalent of chronic conditions. Of the 420 patients, 62% of patients (*n* = 261) had two or more chronic conditions. In addition, more than two-thirds (69%) of patients had private insurance and almost half (49%) of the patients had more than 11 out of a possible 14 program contacts in the 12-month program. As a priori sample size calculation was not performed, post hoc (retrospective) power analysis showed that the study is sufficiently powered (power = 100%, alpha error = 0.05).

At baseline, no significant difference was observed between patients who completed and those who withdrew from the 12-month program. In addition, results of the one-way ANOVA and chi-square tests showed no significant differences by PAM levels with exception for age, private health insurance (PHI) status, glycated haemoglobin (HbA1c), and total cholesterol. Furthermore, the internal consistency of baseline and follow-up PAM in this study was good with Cronbach's alpha coefficients of 0.90 and 0.91 respectively.

Primary outcome {#Sec12}
---------------

### Changes in mean PAM scores {#Sec13}

Of the 626 patients who reported their baseline PAM, 420 (67%) reported PAM levels at program completion. The mean (SD) PAM score at baseline was 57.9 (13.0). Within-group analysis between baseline and follow-up showed significant improvement in mean PAM scores with a mean difference (unadjusted) of 6.8 (95% CI 5.39 to 8.25, *p*-value\< 0.001). After adjusting for potential confounders, the adjusted model showed a significant mean difference of 6.6 (95% CI 5.03 to 8.06, *p*-value\< 0.001) (Table [2](#Tab2){ref-type="table"}). Table 2Repeated measures ANCOVA (main and sensitivity analyses)AnalysisUnadjusted mean difference\
(95% CI)Adjusted mean difference (95% CI)Overall6.82 (5.39, 8.25)\*\*6.55 (5.03, 8.06)\*\*Sensitivity analysis (patients with ≥2 chronic conditions)7.71 (5.99, 9.43)\*\*7.54 (5.72, 9.37)\*\**p*-value\< 0.05\*\**p*-value\< 0.001

Additionally, the sensitivity analysis of patients with two or more chronic conditions (*n* = 261) showed that PAM scores (unadjusted) increased from a mean (SD) of 56.3 (12.02) at baseline to 64.1 (15.2) at 12 months. After adjusting for potential covariates, an adjusted mean difference of 7.54 (95% CI 5.72 to 9.37, *p*-value\< 0.05) was observed (Table [2](#Tab2){ref-type="table"}).

Secondary outcomes {#Sec14}
------------------

### Changes in PAM levels and HARP's self-management impact levels at follow-up {#Sec15}

Cross-tabulation between baseline and follow-up showed significant differences in PAM levels with 43% of patients transitioning from lower to higher levels whereas only 10% transitioned from higher to lower activation levels (*p*-value\< 0.001) (Table [3](#Tab3){ref-type="table"}). More specifically, patients in the WellNet program reported positive change in the PAM levels by significantly increasing from the order of least activated levels (9.2% from Level 1; 24% from Level 2; and 39.2% from Level 3) to the most activated Level 4 at follow-up (*p*-value\< 0.001) (Table [3](#Tab3){ref-type="table"}). Table 3A cross-tabulation table of PAM levels pre- and post-interventionFollow-up PAMBaseline PAMLevel 1 (least activated)Level 2Level 3Level 4 (most activated)Level 114 (18.4)31 (40.8)24 (31.6)7 (9.2)Level 212 (7.8)63 (40.9)42 (27.3)37 (24.0)Level 31 (1.0)10 (10.3)48 (49.5)38 (39.2)Level 40 (0.0)13 (14.0)9 (9.7)71 (76.3)Data represented as N (%)

In terms of the HARP's self-management impact levels, 60% (*n* = 165) of patients in the contemplation/ pre-contemplation level at baseline transitioned to the action and maintenance level at follow-up whereas 64% (*n* = 73) of patients in the preparation level at baseline transitioned to the action and maintenance level at follow-up (Table [4](#Tab4){ref-type="table"}). Furthermore, Pearson's correlation coefficient between PAM and HARP's self-management levels at both baseline and follow-up was less than 0.39 at *p* \< 0.01 significance indicating a weak positive association (Table [5](#Tab5){ref-type="table"}). Table 4A cross-tabulation table of HARP's self-management impact levels pre- and post-interventionFollow-up levelsBaseline levelsContemplation/ pre-contemplationPreparationAction and maintenance**Contemplation/ pre-contemplation**46 (16.8)62 (22.7)165 (60.4)**Preparation**18 (15.8)23 (20.2)73 (64.0)**Action and maintenance**2 (9.5)3 (14.3)16 (76.2)Data represented as N (%)Table 5Correlation test between PAM levels and HARP's self-management levels at baseline and follow-upBaseline PAM levelsFollow-up PAM levelsBaseline HARP levelsFollow-up HARP levels**Baseline PAM levels**1.493\*\*.190\*\*.205\*\***Follow-up PAM levels**.493\*\*1.186\*\*.252\*\***Baseline HARP levels**.190\*\*.186\*\*1.062**Follow-up HARP levels**.205\*\*.252\*\*.0621Pearson's bivariate correlation coefficients\*\**p*-value\< 0.01 (two-tailed test)

### Predictors of change in PAM scores at follow-up {#Sec16}

Results of the multivariable regression analyses showing significant predictors of patient activation levels at follow-up are presented in Table [6](#Tab6){ref-type="table"}. Older age, lack of private health insurance (PHI), and higher baseline PAM score were found to be significant predictors. Increase in patient's age (B = − 0.14, *p* = 0.043) and uninsured patients (B = − 3.41, *p* = 0.033) were significantly associated with decreased PAM scores at follow-up. Conversely, higher baseline PAM score (B = 0.48, *p* \< 0.001) was significantly associated with higher follow-up PAM score (Table [6](#Tab6){ref-type="table"}). Table 6Predictors of patient activation scores at 12-month follow-upPredictors(***N*** = 420)B***p***-valueAge−0.14 (−0.28, −0.01)0.043Insurance status: Uninsured−3.41 (−6.50, − 0.32)0.033Baseline PAM score0.48 (0.37, 0.59)\< 0.001B -- unstandardized beta coefficient (slope)

Discussion {#Sec17}
==========

This study evaluates changes in the activation levels and investigates significant predictors of patient activation among individuals presenting with one or more chronic conditions in primary care across Northern Sydney, Australia following a 12-month enhanced primary care model. Primary care is well established as the forefront of care delivery in Australia, however research with use of primary care data is relatively low. Moreover, GP practice activity in Australia shows that the management rate of chronic conditions was 55 per 100 encounters and that 96% of encounters among patients aged 65 years and above had one or more chronic conditions \[[@CR34]\]. In view of this, the Australian Medical Association (AMA) has acknowledged the importance of primary care as an ideal setting to facilitate patient-centred care and also in educating patients to effectively self-manage their chronic conditions, which could result in better patient outcomes \[[@CR15]\].

The 12-month WellNet intervention resulted in both statistically significant and clinically meaningful improvement in PAM scores with adjusted mean differences in activation score of 6.5 after controlling for potential confounders. There is also evidence showing that each point increase in PAM scores is associated with 2% reduction in hospitalisation and 2% improvement in medication adherence \[[@CR35]\]. In the secondary outcome analyses, there was a statistically significant difference observed between baseline and follow-up PAM levels where 43% of study patients experienced transition from a lower level to a higher level of activation post-intervention. The improvement in patient activation and self-management behaviours in patients is consistent across several other studies that have incorporated core principles of the PCMH model \[[@CR36], [@CR37]\]. Although this study exceeded the MCID and resulted in individual-level transition from one PAM level to another, the follow-up PAM score of 64.6 did not lead to overall sample-level changes as the follow-up score was still in the Level 3 range of PAM. Therefore, there is still more room for improvement in activation which may not have manifested in the relatively short period of 12 months, given, it could take time and sustained education for patients to build confidence to effectively self-manage their chronic illnesses.

In the multivariable regression analyses, increase in age, PHI, and baseline PAM scores were significant predictors of PAM scores at the 12-month follow-up. Increase in years of age as a significant determinant of reduced activation is consistent with findings of studies by Blakemore et al. and Overbeek et al. \[[@CR38], [@CR39]\]. Preliminary qualitative feedback of the WellNet program showed that some elderly patients reported difficulty in engaging with the online GoShare tool and MediTracker mobile application, thereby needing more assistance and coaching to access the electronic educational programs. This could be a plausible explanation as to why elderly patients may have had lower levels of activation at follow-up. Consistent with the above study findings, WellNet group observed a slightly higher mean number of co-existing chronic conditions among patients who were over the median age of 70 years compared to those who were less than or equal to 70 years (2.0 vs 1.8, *p*-value = 0.05).

PHI status was a strong predictor of change in activation levels where uninsured patients were associated with significantly lower activation compared to privately insured patients. This may be due to the reason that patients with PHI coverage may have better access to healthcare in terms of choice of providers and shorter waiting times for treatment compared to those without PHI \[[@CR40], [@CR41]\]. Furthermore, this study is also consistent with findings of studies by Chubak and Rijken et al. which have shown that patients who were activated at baseline had improved activation scores over time \[[@CR42], [@CR43]\].

In comparison to improvements in the PAM levels, a similar positive trend was observed in the HARP's self-management impact and readiness to change assessment item. However, the weak positive association between HARP item and PAM levels could possibly be due to the fact that patients would have better perceived and responded to several specific items of the PAM assessment as opposed to attempting to respond in an overly positive manner on the single item of the HARP assessment.

This study has several strengths and limitations. To our knowledge, the WellNet program is the first of its kind in Australia to evaluate the outcomes of a PCMH model in improving levels of activation and self-management among patients with one or more chronic conditions using GP data. In addition, the program's strengths include large sample size, comprehensive data collection by trained healthcare professionals, and longitudinal measurements rendering determining predictors of change in PAM scores. In terms of the study limitations, the lack of control group means that the possibility of potential bias cannot be excluded, and we cannot be sure that improvement in PAM scores may have occurred anyway without the enhanced PCMH intervention. However, that seems unlikely based on trials conducted with use of control groups which reported similar outcomes \[[@CR20], [@CR44]\]. In addition, some key socio-demographic and socio-economic variables such as education status and income were unavailable for assessment reducing the ability to identify other predictors of change in patient activation. Finally, consistent with other originally designed programs, reproducibility of findings is constrained by potential barriers in the form of uniqueness of data and by patient and provider-level determinants \[[@CR30], [@CR45]\].

Conclusion {#Sec18}
==========

Patient activation is an important precursor not only for effective self-management of chronic conditions but also to empower patients in actively making decisions concerning their health. The integration of GPs and trained CDM coordinators proves critical for provision of individualised care for patients presenting with one or more chronic conditions. This study demonstrates the outcomes of an enhanced primary care model in improving patient activation and self-management outcomes over 12-months. Patients who participated in the WellNet program achieved both statistically significant and clinically meaningful improvements in PAM scores. Findings of this study emphasises the need to increase support for older and uninsured patients in managing their health and healthcare needs. Future research should seek to evaluate the long-term effects and cost-benefits of increased activation in this cohort. Furthermore, additional research is needed to determine disease-specific interactions on patient activation levels. This will render re-designing the level of care to where it is most needed.
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AMA

:   Australian Medical Association

ANOVA

:   Analysis of variance

ANCOVA

:   Analysis of covariance

CC

:   Clinical coordinator

CDM

:   Chronic disease management

CI
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NHS

:   National Health Survey
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